Literature DB >> 3920181

Use of an in-vitro kinetic model to study antibiotic combinations.

S H Zinner, J Blaser, B B Stone, M C Groner.   

Abstract

A two compartment pharmacokinetic model was used to study combinations of piperacillin with N-formimidoyl thienamycin or amikacin, and azlocillin with netilmicin against strains of Pseudomonas aeruginosa. Antibiotic antagonism seen with in-vitro static tests of piperacillin and thienamycin did not occur with the kinetic model. Piperacillin plus amikacin showed enhanced activity, and azlocillin prevented bacterial regrowth seen with netilmicin alone during multiple dosing experiments at high bacterial inocula. This model is useful in the study of antibiotic combinations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920181     DOI: 10.1093/jac/15.suppl_a.221

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 4.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors:  Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

5.  Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.

Authors:  Ali A Alhadab; Mariam A Ahmed; Richard C Brundage
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.

Authors:  J G den Hollander; A M Horrevorts; M L van Goor; H A Verbrugh; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.

Authors:  B J McGrath; E M Bailey; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.